Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmproject jsc - capsule a- ascorbic acid. acetylsalicylic acid. rutoside (rutoside trihydrate), capsule b- metamizole (metamizole sodium monohydrate), calcium gluconate (calcium gluconate monohydrate), diphenhydramine (diphenhydramine hydrochloride) - capsules - 300mg+ 250mg+ 20mg+ 250mg+ 100mg+ 20mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: sorbitol; sodium propyl hydroxybenzoate; sodium methyl hydroxybenzoate; saccharin sodium; brilliant scarlet 4r; purified water; sucrose; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tacrolimus monohydrate, quantity: 2.044 mg (equivalent: tacrolimus, qty 2 mg) - capsule - excipient ingredients: hypromellose; croscarmellose sodium; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; brilliant blue fcf; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tacrolimus monohydrate, quantity: 0.767 mg (equivalent: tacrolimus, qty 0.75 mg) - capsule - excipient ingredients: hypromellose; croscarmellose sodium; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; brilliant blue fcf; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tacrolimus monohydrate, quantity: 5.11 mg (equivalent: tacrolimus, qty 5 mg) - capsule, hard - excipient ingredients: hypromellose; magnesium stearate; croscarmellose sodium; lactose monohydrate; shellac; ethanol absolute; isopropyl alcohol; butan-1-ol; propylene glycol; strong ammonia solution; iron oxide black; potassium hydroxide; purified water; titanium dioxide; sorbitan monolaurate; iron oxide red; potable water; gelatin; sodium lauryl sulfate - adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - metamizole sodium (unii: vsu62z74on) (metamizole - unii:934t64rmnj) - metamizole 495 g in 500 g

United States - English - NLM (National Library of Medicine)

american pharmaceutical ingredients llc - metamizole sodium (unii: vsu62z74on) (metamizole sodium - unii:vsu62z74on) -

United States - English - NLM (National Library of Medicine)

professional group of pharmacists new york llc - metamizole sodium (unii: vsu62z74on) (metamizole - unii:934t64rmnj) -

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - sodium valproate 100mg - tablet - 100 mg - active: sodium valproate 100mg excipient: hydrated silica light kaolin magnesium stearate maize starch purified water - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - sodium valproate 199.8mg; valproic acid 87mg (as navalproate 100.3mg) - modified release tablet - 300 mg - active: sodium valproate 199.8mg valproic acid 87mg (as navalproate 100.3mg) excipient: erythrosine ethylcellulose hydrated silica hypromellose   indigo carmine iron oxide black propylene glycol purified water titanium dioxide - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.